Virus-like particles expressing the nucleocapsid gene as an efficient vaccine against Rift Valley fever virus

Vector-Borne and Zoonotic Diseases

Volumn 10, Issue 7, 2010, Pages 701-703

  Pichlmair, Andreas ^a   Habjan, Matthias ^b   Unger, Hermann ^c   Weber, Friedemann ^b  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b UNIVERSITY OF FREIBURG   (Germany)

^c INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

Author keywords

Nucleocapsid gene N; Phlebovirus; Rift Valley fever virus; Vaccine; Virus like particles

Indexed keywords

NUCLEOCAPSID PROTEIN; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; LETHAL DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; VIRUS LIKE AGENT; VIRUS NUCLEOCAPSID;

ANIMALS; CELL LINE; CRICETINAE; HUMANS; MICE; NUCLEOCAPSID PROTEINS; RIFT VALLEY FEVER; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

BUNYAVIRIDAE; MUS; PHLEBOVIRUS; RIFT VALLEY FEVER VIRUS;

EID: 77957567347     PISSN: 15303667     EISSN: None     Source Type: Journal    
DOI: 10.1089/vbz.2009.0248     Document Type: Article

References (15)

1. Bird, BH, Albarino, CG, Hartman, AL, Erickson, BR, et al. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 2008; 82:2681-2691.
2. Bird, BH, Ksiazek, TG, Nichol, ST, Maclachlan, NJ. Rift Valley fever virus. J Am Vet Med Assoc 2009; 234:883-893.
3. Bouloy, M, Flick, R. Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antivir Res 2009; 84:101-118.
4. Elliott, RM, Weber, F. Bunyaviruses and the type I interferon system. Viruses 2009; 1:1003-1021.
5. Gorchakov, R, Volkova, E, Yun, N, Petrakova, O, et al. Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins. Virology 2007; 366:212-225.
6. Gori Savellini, G, Di Genova, G, Terrosi, C, Di Bonito, P, et al. Immunization with Toscana virus N-Gc proteins protects mice against virus challenge. Virology 2008; 375:521-528.
7. Habjan, M, Penski, N, Spiegel, M, Weber, F. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. J Gen Virol 2008; 89:2157-2166.
8. Habjan, M, Penski, N, Wagner, V, Spiegel, M, et al. Efficient production of Rift Valley fever virus-like particles: the antiviral protein MxA can inhibit primary transcription of bunyaviruses. Virology 2009; 385:400-408.
9. Heise, MT, Whitmore, A, Thompson, J, Parsons, M, et al. An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus. Epidemiol Infect 2009; 137:1309-1318.
10. Ikegami, T, Makino, S. Rift valley fever vaccines. Vaccine 2009; 27 SUPPL. 4:D69-D72.
11. Lagerqvist, N, Naslund, J, Lundkvist, A, Bouloy, M, et al. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol J 2009; 6:6.
12. Naslund, J, Lagerqvist, N, Habjan, M, Lundkvist, A, et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 2009; 385:409-415.
13. Roy, P, Noad, R. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccine 2008; 4:5-12.
14. Spik, K, Shurtleff, A, McElroy, AK, Guttieri, MC, et al. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 2006; 24:4657-4666.
15. Wallace, DB, Ellis, CE, Espach, A, Smith, SJ, et al. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 2006; 24:7181-7189.